Abnormal Blood Glucose Risk and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder

Reviewed by ExomeDNA Editorial Process · [/methodology/editorial-process]

Last reviewed: 2026-05-29

This content is educational and informational. For health decisions, consult a clinician.

Abnormal Blood Glucose Risk is a metabolic trait reflecting the genetic factors that influence blood glucose levels outside the normal range — a condition that does not yet meet full clinical criteria for diabetes but represents a meaningful shift in how the body regulates sugar. Large-scale genomic research has identified multiple genes, including G6PC2, MTNR1B, and TCF7L2, that shape glucose metabolism at the population level. This page covers the biology behind glucose regulation, what the published science says, and how understanding genetic predisposition fits into a broader picture of metabolic health.

What is Abnormal Blood Glucose?

Abnormal blood glucose refers to circulating blood sugar levels that fall outside accepted normal ranges — either elevated (hyperglycemia) or, less commonly in this context, lower than expected (hypoglycemia). In clinical practice, elevated fasting glucose below full Type 2 Diabetes thresholds is often termed impaired fasting glucose or prediabetes. Genetics contributes meaningfully to where an individual's glucose set point lands, independent of diet or lifestyle.

Blood glucose regulation involves a finely tuned system: the pancreas senses circulating glucose and releases insulin to signal cells to absorb it. Genes involved in pancreatic beta-cell function, glucose phosphorylation, and insulin secretion all influence how tightly this system is maintained. Common genetic variants in several well-characterized genes have been associated with measurable differences in fasting glucose levels across large population studies.

The Genetics Behind Abnormal Blood Glucose

Several genes carry strong signals in genome-wide association research for blood glucose regulation.

G6PC2 (Glucose-6-Phosphatase Catalytic Subunit 2) encodes an enzyme within the glucose-6-phosphatase multicomponent system — a key regulator of glucose cycling in pancreatic beta cells. Variants near this gene are among the most consistently replicated signals for fasting glucose levels in population studies. The gene's function connects directly to how beta cells sense and respond to circulating glucose.

MTNR1B encodes the melatonin receptor 1B, a G-protein-coupled receptor expressed in pancreatic islets. Melatonin signaling through this receptor has been shown to inhibit insulin secretion. Common variants near MTNR1B are strongly associated with elevated fasting glucose levels, pointing to an unexpected link between circadian biology and glucose homeostasis.

TCF7L2 (Transcription Factor 7 Like 2) is one of the most well-studied genetic loci in metabolic disease research. It encodes a transcription factor involved in the WNT signaling pathway, which plays a role in beta-cell development and incretin hormone signaling. Variants in this gene are associated with altered insulin secretion and elevated glucose.

GCK (Glucokinase) phosphorylates glucose as the first step in glucose metabolism and acts as the pancreatic glucose sensor. Variants in this gene are linked to subtle but heritable shifts in the glucose set point — a phenotype sometimes called glucokinase-associated fasting hyperglycemia.

HK1 (Hexokinase 1) is another member of the hexokinase family involved in glucose phosphorylation. Population-level signals near HK1 have been associated with fasting glucose variation, adding to the picture of how glucose metabolism genes collectively shape the trait.

Additional genes with evidence in this signal landscape include FOXA2, a transcription factor involved in pancreatic development, and YKT6, implicated through expression quantitative trait loci near a glucose-associated locus.

What the Research Says

Research base: Robust.

The genetic architecture of blood glucose regulation has been characterized extensively in large-scale genomic studies. A 2024 analysis of over one million participants in the VA Million Veteran Program examined the genetic architecture of more than 2,000 traits across diverse ancestries, providing one of the most comprehensive multi-ancestry characterizations of metabolic phenotypes to date, including abnormal blood glucose.^[1]

KEY STAT The VA Million Veteran Program study examined genetic associations across 2,068 traits in a diverse cohort, with glucose-related phenotypes among the most heritably characterized metabolic outcomes (Verma 2024^[1]).

The combined evidence from decades of GWAS research identifies the G6PC2 locus as one of the strongest and most replicated signals for fasting glucose levels in the general population. MTNR1B variants have been replicated across multiple large cohorts and ethnicities, consistently showing association with elevated fasting glucose. TCF7L2 variants, similarly, have been studied in depth and are associated with altered pancreatic beta-cell function and insulin secretion dynamics.

The robustness of this research base means that the population-level signals from these loci are well-established, though individual genetic results always represent probabilistic contributions rather than deterministic outcomes.

KEY STAT Variants near MTNR1B — the melatonin receptor gene — have been linked to elevated fasting glucose in studies spanning multiple global populations, highlighting how circadian biology intersects with metabolic regulation (Verma 2024^[1]).

How Abnormal Blood Glucose Affects You

Blood glucose levels that remain persistently elevated, even below the threshold for Type 2 Diabetes, are associated over time with effects on vascular function, kidney health, and cardiovascular risk. The spectrum from normal glucose through impaired fasting glucose to Type 2 Diabetes is not a sharp step but a continuum — where someone sits on that continuum reflects both genetic predisposition and accumulated lifestyle and environmental factors.

From a genetic standpoint, variants in genes like G6PC2 and MTNR1B tend to influence glucose primarily at the fasting state, reflecting the role of these genes in overnight glucose cycling and nocturnal insulin suppression. TCF7L2 variants, by contrast, appear more strongly connected to post-meal insulin secretion dynamics, meaning their influence may manifest differently depending on dietary patterns.

For people with elevated genetic polygenic signals for this trait, the elevated risk is modest in absolute terms — genetic predisposition is one layer of a multifactorial picture that includes body composition, sleep quality, dietary carbohydrate load, physical activity, and age. Understanding the genetic component helps contextualize individual variability, particularly for people who experience elevated glucose without obvious lifestyle contributors.

The melatonin connection through MTNR1B is worth noting separately: research into this locus has prompted investigation into whether late-night eating habits interact with melatonin signaling to worsen glucose homeostasis in people carrying the at-risk variant — an active area of nutrition-gene interaction research.

Working With Your Abnormal Blood Glucose Profile

Understanding a genetic predisposition toward elevated blood glucose is most useful as one input among several when thinking about metabolic wellness. A clinician is the appropriate guide for any monitoring plan or intervention — a genetic result should prompt a conversation, not a conclusion.

Several modifiable factors are consistently associated with blood glucose regulation and are broadly supported by research:

Physical activity improves insulin sensitivity through multiple pathways independent of weight change. Even moderate aerobic activity and resistance training have documented effects on fasting glucose.

Dietary composition influences post-meal glucose response significantly. Lower glycemic index diets, higher dietary fiber, and reduced refined carbohydrate loads are associated with lower average glucose levels in large observational studies.

Sleep quality and duration intersect directly with the melatonin-glucose axis implicated by MTNR1B genetics. Consistent sleep timing and adequate sleep duration are associated with better glucose regulation in population research.

Body composition — particularly visceral adiposity — is a strong independent driver of insulin resistance, which amplifies the effects of impaired glucose regulation. Even modest reductions in visceral fat are associated with measurable glucose improvements.

None of these recommendations are specific to genetic risk status. They represent well-supported metabolic health practices that apply broadly. For people with a genetic profile suggesting elevated glucose predisposition, discussing routine fasting glucose monitoring with a healthcare provider is a reasonable conversation to have.

Abnormal blood glucose does not exist in isolation — it sits within a broader metabolic constellation. Several related traits on the ExomeDNA platform share genetic and biological overlap with this one.

Type 2 Diabetes Risk [/traits/type-2-diabetes-risk] is the downstream endpoint that abnormal glucose predisposition most closely precedes. TCF7L2, GCK, and MTNR1B are all prominent in Type 2 Diabetes GWAS as well, reflecting shared genetic architecture between subclinical glucose elevation and confirmed diabetes.

Insulin Resistance [/traits/insulin-resistance] represents a related but distinct phenotype — the cellular failure to respond to insulin signals efficiently — that frequently co-occurs with elevated glucose and shares loci in the TM6SF2 and FOXA2 neighborhoods.

Fasting Insulin Levels [/traits/fasting-insulin-levels] is closely connected to glucose regulation, with FOXA2 featuring in both phenotypes given its role in pancreatic development and glucagon regulation.

Triglyceride Levels [/traits/triglyceride-levels] and HDL Cholesterol [/traits/hdl-cholesterol] both show metabolic crosstalk with glucose traits — the cluster of elevated glucose, elevated triglycerides, and low HDL is a hallmark of metabolic syndrome, a phenotype with its own GWAS architecture.

For gene-level context, the GCK gene page [/genes/gck] provides a deeper look at how glucokinase variants are studied in the context of both glucose regulation and rare monogenic forms of fasting hyperglycemia.

Frequently Asked Questions

What does it mean to have a higher genetic score for abnormal blood glucose?

A higher genetic score for this trait means that, across a population of people with similar genetic profiles, average fasting glucose levels tend to run slightly higher. This is a population-level observation, not a prediction for any individual. Many people with elevated genetic scores maintain normal blood glucose throughout their lives, especially with active attention to metabolic health factors. The score is best used as one piece of context, not a forecast — and a conversation with a clinician is the appropriate next step for anyone concerned about their glucose levels.

Are the genes involved in blood glucose regulation the same as those for Type 2 Diabetes?

There is substantial overlap. TCF7L2, GCK, and MTNR1B all appear prominently in both the blood glucose regulation literature and the Type 2 Diabetes GWAS landscape. This makes biological sense: abnormal fasting glucose is on the continuum toward Type 2 Diabetes, and many of the same gene pathways are involved. However, there are also loci more specific to one phenotype than the other — glucose regulation genetics captures pancreatic sensing and secretion biology in a somewhat broader way than the diabetes endpoint alone.

What role does melatonin play in blood glucose, and why does MTNR1B matter?

Melatonin receptor 1B (MTNR1B) is expressed in pancreatic beta cells, where melatonin signaling through this receptor inhibits insulin release. Common variants near MTNR1B are associated with elevated fasting glucose in large population studies. The leading hypothesis is that in people carrying the at-risk allele, melatonin signaling more potently suppresses overnight insulin secretion, leaving glucose slightly higher in the fasting state. This has generated research interest in meal timing — specifically whether eating late when melatonin is elevated may be a more relevant lifestyle factor for this genetic subgroup.

Can diet changes affect blood glucose even for people with a genetic predisposition?

Research consistently shows that dietary patterns influence blood glucose levels in people across the genetic spectrum. Lower glycemic index foods, higher fiber intake, and reduced refined carbohydrate loads are associated with lower average glucose across large observational studies. Genetic predisposition does not override lifestyle factors — rather, it may mean some people need to be more intentional about these practices to achieve the same glucose outcomes. This is why metabolic health strategies that combine diet, physical activity, and sleep quality tend to be more effective than any single intervention.

Is abnormal blood glucose the same as prediabetes?

The terms are related but not identical. Prediabetes is a clinical designation based on specific fasting glucose or HbA1c thresholds set by medical guidelines. The GWAS trait "abnormal blood glucose" studied in population genomics captures a broader phenotype — any glucose reading falling outside the normal reference range, including those that may not reach formal prediabetes criteria. The genetic signals identified for this trait are nonetheless highly relevant to prediabetes biology, since many of the same loci and pathways are implicated. Whether a specific glucose reading constitutes prediabetes is a determination made through clinical testing, not genetic analysis.

Does genetic risk for abnormal blood glucose mean someone will develop diabetes?

Genetic risk scores for blood glucose elevation reflect population-level associations — they do not determine individual outcomes. Many people with elevated genetic scores for this trait never progress to Type 2 Diabetes, while some people with lower scores may develop diabetes due to other factors. Genetics is one layer among many that include body composition, physical activity, dietary habits, sleep, and age. A genetic predisposition is most usefully understood as a prompt to stay attentive to modifiable metabolic health factors, ideally with the guidance of a healthcare provider.

References

[1] Verma et al. Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. Science. 2024. PMID: 39024449.

Data sources:

GWAS Catalog (NHGRI-EBI, accessed 2026-05-29)
Open Targets Platform (CC0 1.0, accessed 2026-05-29)
ClinVar (NCBI, accessed 2026-05-29) — entries at ≥2-star review status
ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-29)

By the ExomeDNA Research Team

FDA wellness compliance statement: This content is intended for educational and informational purposes only. ExomeDNA's genetic reports are wellness products, not clinical tools, and are not substitutes for professional health guidance. Genetic variants discussed reflect population-level associations from published research. Individual genetic results should be interpreted with the guidance of a qualified healthcare provider.

Browse all traits →